SecBot SecBot

XCUR drug pipeline

EXICURE, INC. · 1 rated drug
$1.07
−0.9% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2
Time to marketNo timeline is estimable. The drug is still at Phase 2 with no announced Phase 3 plan under Exicure. The program is being sold to GPCRT Inc., making any go-to-market timeline dependent on the buyer's development strategy.

GPC-100 burixafor Updated Nov 14

What to watch

Watch the November 16, 2026 interim payment deadline (KRW 2.0 billion) as a sign of deal commitment from GPCRT Inc., and the November 30, 2026 expected closing. If the deal closes, Exicure will have ~$4.8M cash but no operating assets. If it fails, Exicure faces a severe liquidity crunch with no pipeline and an active Nasdaq delisting notice.

Bull case
  • GPC-100 (burixafor) showed positive Phase 2 topline data at the December 2025 ASH meeting, with nearly 90% stem cell mobilization in multiple myeloma patients, suggesting meaningful clinical activity.
  • The KRW 6.5 billion (~$4.8M) asset sale to GPCRT Inc. provides a cash infusion worth roughly 80% of Exicure's market cap, potentially extending the company's runway.
  • The drug's CXCR4 mechanism is a validated target for stem cell mobilization, similar to approved drugs like plerixafor (Mozobil).
Bear case
  • Exicure is selling the GPC-100 program because it cannot fund further development; the company had only $3.7M in cash as of early 2026 and received a Nasdaq delisting notice in September 2026.
  • After the sale closes, Exicure will have no active drug pipeline, raising going-concern and reverse-merger-or-liquidation risk.
  • The company retains ~$1.4M in pre-September 2026 program liabilities (unpaid CRO fees of $644K and sublease obligations of $783K), and the deal could still fail to close.